We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Delaware federal court ruled that Mylan’s efforts to develop a generic version of Forest Laboratories’ Savella infringed on three of the company’s patents. Read More
Horizon Therapeutics has filed suit against Par Pharmaceutical, alleging infringement of three patents for its urea cycle disorders drug Ravicti. Read More
Forest Laboratories has decided to bury the hatchet with Teva Pharmaceuticals USA and Mayne Pharma, settling a two-and-a-half year-long patent dispute for undisclosed terms. Read More
Less than 24 hours after finalizing its acquisition of Allergan’s generics division, Teva Pharmaceutical disclosed plans to pick up the company’s distribution arm for $500 million. Read More